NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
